Harbour BioMed has signed a collaboration agreement with Kelun-Biotech Biopharmaceutical to develop and commercialise A167, an anti-PD-L1 antibody indicated for the treatment of cancer.
Harbour BioMed will make an upfront payment of $350m excluding royalties to Kelun-Biotech, as per the deal.
Harbour will hold exclusive manufacturing and commercialisation rights of A167 outside Greater China, as part of the collaboration.
Based in China, Sichuan Kelun-Biotech is a biopharmaceutical company and a subsidiary of Kelun Pharmaceutical Group, while Harbour BioMed, also based in China, is a developer of therapeutics for cancer.
The collaboration will work towards the development of therapies that involve the combination of anti-PD-L1 antibody with other agents.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData
Norway-based financing firm Coalition for Epidemic Preparedness Innovations (CEPI) has awarded a $36m contract to Emergent BioSolutions and Profectus BioSciences for the development of the Lassa virus vaccine.
Profectus will receive funding from CEPI for the development of its VesiculoVax-vectored vaccine used for the prevention of Lassa virus infection, as part of the agreement. Emergent will provide technical and manufacturing support, as well as development support for the Profectus vaccine.
Based in the US, Emergent BioSolutions is a developer of vaccines and immune globulins, while Profectus BioSciences, also based in the US, is a clinical-stage vaccine development company.
The collaboration will address the unmet medical need of patients for the Lassa virus vaccine.
Sierra Oncology has completed the acquisition of momelotinib drug from Gilead Sciences in a deal valued at $198m.
Gilead will receive a $3m upfront payment and $195m in milestone payments, upon commercialisation of the drug.
Momelotinib is a janus kinase (JAK) 1/2 and activin receptor Type 1 (ACVR1) inhibitor indicated for the treatment of myelofibrosis.
Based in Canada, Sierra is a clinical-stage drug development company engaged in the development of therapies for cancer, while Gilead is a US-based biopharmaceutical company that develops and manufactures novel medicines.
The acquisition will be a complementary addition to Sierra’s oncology drug portfolio and enables it to become a diversified late-stage drug development company.